Invention Grant
- Patent Title: Kinase inhibitors
-
Application No.: US15207915Application Date: 2016-07-12
-
Publication No.: US09850233B2Publication Date: 2017-12-26
- Inventor: Matthew Colin Thor Fyfe
- Applicant: Respivert Limited , Topivert Pharma Limited
- Applicant Address: GB High Wycombe, Buckinghamshire GB London
- Assignee: Respivert Limited,Topivert Pharma Limited
- Current Assignee: Respivert Limited,Topivert Pharma Limited
- Current Assignee Address: GB High Wycombe, Buckinghamshire GB London
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: GB1314700.4 20130816; GB1322684.0 20131220
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D403/12 ; A61K31/506 ; A61K31/5377 ; C07D401/14 ; A61K31/4439 ; A61K31/675 ; A61K45/06 ; C07F9/46

Abstract:
There are provided compounds of formula I, wherein: Y represents NR2R3; one of R2 and R3 represents —[C2-4 alkylene-O]1-12—[C2-4 alkylene]-R2a and the other of R2 and R3 has a meaning given in the description; and R, R1, R2a, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
Public/Granted literature
- US20160318909A1 KINASE INHIBITORS Public/Granted day:2016-11-03
Information query